AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29246818
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of DMPA
Trial: 29246818
Drug: Clinic administration
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic administration of DMPA
Trial: 28355979
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy care
Trial: 28355979
Drug: SBST administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBST administered at different time points
Trial: 24434827
Drug: Daily feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily feedback messages (DFB group; n = 70)
Trial: 22509750
Drug: 0.5% MF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% MF gel
Trial: 22509750
Drug: 1% MF
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1% MF gel
Trial: 22509750
Drug: 1.5% MF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% MF gel
Trial: 21365405
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care program (quarterly follow-up by a hospital pharmacist for 9 months)
Trial: 21365405
Drug: No pharmaceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pharmaceutical care (control group)
Trial: 14576536
Drug: 0.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 mg/kg succinylcholine (saline control)
Trial: 14576536
Drug: 0.24 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.24 mg/kg succinylcholine
Trial: 3937549
Drug: Terfenadine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (60 mg, oral, twice daily)
Trial: 27887597
Drug: Ability Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ability Program (tablet-delivered cognitive activities 5 days/week, physical activities 7 days/week)
Trial: 27887597
Drug: Treatment As
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment As Usual (TAU) (paper and pencil cognitive activities 5 days/week, clinician's prescribed physical exercise daily)
Trial: 9388311
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (dextran, nicotinic acid, aspirin, dipyridamole, radix salviae miltiorrhizae composita)
Trial: 27077879
Drug: 25 mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mL/day of PC-enriched OO containing 500 mg PC/kg (FVOO)
Trial: 27077879
Drug: 25 mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mL/day of OO containing 80 mg PC/kg (VOO)
Trial: 27077879
Drug: 25 mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mL/day of OO containing a mixture of 500 mg PC/kg from OO and thyme (FVOOT)
Trial: 22422361
Drug: Dolutegravir 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 250 mg suspension
Trial: 22422361
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg tablet
Trial: 21252455
Drug: Short-course acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-course acyclovir therapy (800 mg five times a day for four days)
Trial: 9307221
Drug: poly(L-lactide) osteosynthesis
RxNorm normalized name: L-(-)-lactide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: poly(L-lactide) osteosynthesis plug
Trial: 8354200
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vitamins A and E (5000 IU + 100 IU)
Trial: 8354200
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg of beta-carotene
Trial: 2872913
Drug: Both implant
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both implant groups (Groups B and C)
Trial: 30789384
Drug: Mannitol 0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 0.7 g/kg
Trial: 30789384
Drug: Mannitol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 1.0 g/kg
Trial: 30789384
Drug: Mannitol 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 1.4 g/kg
Trial: 20026804
Drug: Azacitidine 75
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 75 mg/m²/d
Trial: 16001233
Drug: Tesaglitazar 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tesaglitazar 1.0 mg/day
Trial: 12556267
Drug: 2-implant overdenture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-implant overdenture
Trial: 10657821
Drug: Intranasal live
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal live attenuated influenza vaccine
Trial: 1500660
Drug: Other antacids
RxNorm normalized name: ANTACIDS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antacids (magnesium hydroxide and aluminum hydroxide)
Trial: 25765698
Drug: Clinic plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic plus community support (screening for serum cryptococcal antigen, antifungal therapy for positive cases, weekly home visits for 4 weeks)
Trial: 23340440
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) gel, 0.5mL injection
Trial: 19386741
Drug: Oligofructose supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligofructose supplementation (21 g/d)
Trial: 18596121
Drug: multitarget therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multitarget therapy (mycophenolate mofetil, tacrolimus, and steroids)
Trial: 18596121
Drug: intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous cyclophosphamide (IVCY)
Trial: 1951163
Drug: Fish-oil concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil concentrate (FOC) supplemented with 15 mg alpha-tocopherol/d for 10 weeks
Trial: 1951163
Drug: Fish-oil concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil concentrate (FOC) plus an additional 200 mg alpha-tocopherol/d for 8 weeks (FOC+E)
Trial: 7033573
Drug: Allopurinol during
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol during chemotherapy
Trial: 7033573
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no allopurinol) during chemotherapy
Trial: 26186592
Drug: Rikkunshito 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rikkunshito 5.0 g/day
Trial: 26186592
Drug: Rikkunshito 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rikkunshito 2.5 g/day
Trial: 27105601
Drug: Baclofen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (30 mg)
Trial: 27105601
Drug: Chlordiazepoxide (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide (75 mg)
Trial: 19001508
Drug: Irbesartan 300
RxNorm normalized name: irbesartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 300 mg per day
Trial: 15917194
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1 g intravenous infusion for 45 min)
Trial: 8942013
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calcium, vitamin D3, and ascorbic acid supplementation
Trial: 1705725
Drug: Conventional fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionated radiation (Group I); 1.8 to 2.3 Gy once a day, total dose 30 to 40 Gy, average treatment duration 20 days
Trial: 1705725
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation (Group II); 1.8 to 2 Gy two times a day, total dose 25 to 35 Gy, average treatment duration 10 days
Trial: 30267478
Drug: Diazepam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.2 mg/kg i.v., maximum 8 mg)
Trial: 30267478
Drug: Label dosing
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Label dosing of Diazepam
Trial: 23221187
Drug: 10% povidone
RxNorm normalized name: POVIDONE-IODINE 100 mg in 1 mL TOPICAL LIQUID [Saninta 10% Povidone-Iodine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% povidone iodine aqueous solution (PI)
Trial: 16638499
Drug: Prednisone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (2 mg/kg/day for 4 weeks)
Trial: 10949538
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) melatonin, average final dose 5.7 mg (2-12 mg)
Trial: 2864857
Drug: Nifedipine monotherapy
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine monotherapy (10 mg three times daily)
Trial: 2864857
Drug: Metoprolol monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol monotherapy (100 mg twice daily)
Trial: 2864857
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (100 mg metoprolol twice daily plus 10 mg nifedipine three times daily)
Trial: 20809058
Drug: Control rTMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control rTMS (sham treatment)
Trial: 12663288
Drug: Fortified beverage
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fortified beverage with 10 micronutrients at physiologic doses
Trial: 8650875
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of normal saline (15 mL/kg)
Trial: 8650875
Drug: Furosemide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (1 mg/kg; maximum, 40 mg)
Trial: 1632390
Drug: IS-5-MN (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IS-5-MN (20 mg) at 8 a.m.
Trial: 1632390
Drug: IS-5-MN (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IS-5-MN (20 mg) at 2 p.m.
Trial: 4056843
Drug: Recombinant DNA-derived
RxNorm normalized name: somatropin (recombinant DNA origin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA-derived interferon alpha (rIFN alpha A) at a low dose of 2 X 10(6) U/m2 intramuscularly daily
Trial: 4056843
Drug: Recombinant DNA-derived
RxNorm normalized name: somatropin (recombinant DNA origin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA-derived interferon alpha (rIFN alpha A) at a high dose of 20 X 10(6) U/m2 intramuscularly daily
Trial: 4056843
Drug: Recombinant DNA-derived
RxNorm normalized name: somatropin (recombinant DNA origin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA-derived interferon alpha (rIFN alpha A) at a high dose (20 X 10(6) U/m2)
Trial: 28795387
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg/day orally) plus Fuzheng Kang'ai Formula (250 mL, twice per day, orally)
Trial: 20123223
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (turning by nursing staff)
Trial: 16361173
Drug: Penehyclidine hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Penequinine, Penehyclidine (DB16287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penehyclidine hydrochloride (PH) 0.02 mg/kg combined with neostigmine 0.03 mg/kg
Trial: 16361173
Drug: Atropine 0.02
RxNorm normalized name: ATROPINE 0.025/DIFENOXIN 1MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.02 mg/kg combined with neostigmine 0.03 mg/kg
Trial: 12143227
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg terlipressin i.v. every 4 hours for 2 days (group I)
Trial: 12143227
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg terlipressin i.v. every 4 hours for 5 days (group II)
Trial: 9491067
Drug: White dawn
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White dawn treatment (1.5 hours from 4:30 a.m. to 6:00 a.m. peaking at 250 lux)
Trial: 9491067
Drug: Dim red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim red dawn treatment (1.5 hours from 4:30 a.m. to 6:00 a.m. peaking at 2 lux)
Trial: 9491067
Drug: White dawn
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White dawn treatment
Trial: 7923305
Drug: Standard nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nicardipine tablets
Trial: 3044874
Drug: Dipyrone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone (500 mg)
Trial: 11811084
Drug: Standard eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard eradication treatment (lansaprasol 30 mg bid, clarithromycin 500 mg bid, amoxicillin 1 g bid for 14 days)
Trial: 11811084
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) 1000 mg/day plus standard treatment
Trial: 11811084
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) 1000 mg/day for 14 days
Trial: 11811084
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen plus beta carotene (BC) 120 mg/day
Trial: 11811084
Drug: Beta carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta carotene (BC) 120 mg/day for 14 days
Trial: 30589387
Drug: 4-week rehabilitation
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week rehabilitation program consisting of ankle stretching and strengthening, balance training, and joint mobilizations, with daily home ankle-strengthening and stretching exercises.
Trial: 29708388
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation treatment plus exercise intervention (ST + EX)
Trial: 29708388
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation treatment plus wellness education (ST + CTRL)
Trial: 17389305
Drug: LY451395 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY451395 0.2 mg BID for 28 days and 1.0 mg BID thereafter (n = 90)
Trial: 14693973
Drug: Traditional primary
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional primary care treatment (Control)
Trial: 12154416
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (n = 188)
Trial: 8206467
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (70% ethanolic vehicle)
Trial: 129853
Drug: Spectinomycin hydrochloride
RxNorm normalized name: Spectinomycin Hydrochloride
DrugBank: Spectinomycin (DB00919)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spectinomycin hydrochloride (2.0 g)
Trial: 31676651
Drug: Full HPSF
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full HPSF (daily healthy lunch and structured physical activity sessions)
Trial: 28448266
Drug: Transdermal Continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal Continuous Oxygen Therapy (TCOT)
Trial: 28448266
Drug: Moist Wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moist Wound Therapy (MWT) with sham device (control)
Trial: 16863564
Drug: Bifidobacterium infantis
RxNorm normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium infantis 35624 at a dose of 1 x 10(8) cfu/mL
Trial: 16863564
Drug: Bifidobacterium infantis
RxNorm normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium infantis 35624 at a dose of 1 x 10(6) cfu/mL
Trial: 16863564
Drug: Bifidobacterium infantis
RxNorm normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium infantis 35624 at a dose of 1 x 10(10) cfu/mL
Trial: 3015019
Drug: Daily acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily acyclovir treatment (200 mg t.i.d.)
Trial: 3015019
Drug: Weekend acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekend acyclovir treatment (400 mg t.i.d. on Saturday and Sunday)
Trial: 30286746
Drug: Managing multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Managing multiple medications
Trial: 16190390
Drug: General therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General therapy and UTI after hemorrhage (Group II)
Trial: 16190390
Drug: General therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General therapy (Group I)
Trial: 12204667
Drug: Continue tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue tamoxifen treatment
Trial: 12204667
Drug: Stop tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop tamoxifen treatment
Trial: 10527998
Drug: HGF concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGF concentrations in SGA group (16.9 ± 6.6 ng/ml)
Trial: 10527998
Drug: HGF concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGF concentrations in AGA group (16.7 ± 9.0 ng/ml)
Trial: 10527998
Drug: HGF concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGF concentrations in LGA group (20.2 ± 14.8 ng/ml)
Trial: 7424807
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (45 g protein)
Trial: 7424807
Drug: Sulfur amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfur amino acid supplement (15 g protein plus sulfur amino acids)
Trial: 7424807
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (15 g protein)
Trial: 31274775
Drug: Levosimendan (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.1 µg/kg/min)
Trial: 31274775
Drug: Milrinone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (0.4 µg/kg/min)
Trial: 28898204
Drug: Beraprost sodium
RxNorm normalized name: beraprost sodium
DrugBank: Beraprost (DB05229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beraprost sodium (BPS) plus Aspirin (40 μg, tid and 100 mg, qd)
Trial: 26135078
Drug: Internet usage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet usage (not specified if treatment or control).
Trial: 17902062
Drug: Potassium-magnesium-aspartate solution
RxNorm normalized name: potassium magnesium aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium-magnesium-aspartate solution (Inzolen)
Trial: 7950508
Drug: Hydrocortisone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (30 mg/day)
Trial: 7950508
Drug: Prednisone (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (7.5 mg/day)
Trial: 3604885
Drug: Sotalol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (160 to 800 mg/day, median 323 mg, mean 386 mg)
Trial: 236804
Drug: Metiamide 1
RxNorm normalized name: metrizamide
DrugBank: Metrizamide (DB01578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metiamide 1 g daily by mouth
Trial: 21272413
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate supplementation (15 mg/d)
Trial: 21272413
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate supplementation (30 mg/d)
Trial: 11384788
Drug: Incentives to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentives to improve follow-up for tuberculosis therapy after release from jail
Trial: 11384788
Drug: Outreach efforts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outreach efforts in shelters and drug/alcohol programs
Trial: 9400508
Drug: Doxorubicin-based adjuvant
RxNorm normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin-based adjuvant chemotherapy
Trial: 8121914
Drug: 32P with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32P with low-dose hydroxy-urea (500 mg/day) maintenance therapy
Trial: 8121914
Drug: 32P without
RxNorm normalized name: Sodium phosphate (32P)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 32P without hydroxy-urea maintenance therapy